190 related articles for article (PubMed ID: 29927462)
1. CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M).
Pereira EM; Silva ASD; Silva RND; Monte Neto JT; Nascimento FFD; Sousa JLM; Costa Filho HCSAL; Sales Filho HLA; Labilloy A; Monte SJHD
J Bras Nefrol; 2018; 40(4):333-338. PubMed ID: 29927462
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
3. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
4. Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease.
Üçeyler N; Böttger J; Henkel L; Langjahr M; Mayer C; Nordbeck P; Wanner C; Sommer C
J Intern Med; 2018 Oct; 284(4):427-438. PubMed ID: 29974530
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy.
Thomaidis T; Relle M; Golbas M; Brochhausen C; Galle PR; Beck M; Schwarting A
Kidney Int; 2009 Feb; 75(4):399-407. PubMed ID: 19037253
[TBL] [Abstract][Full Text] [Related]
6. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
8. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
9. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
10. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
12. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
13. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.
Deng M; Zhou H; Liang Z; Li Z; Wang Y; Guo W; Zhao AY; Li F; Mu Y; Zhao AZ
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671438
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
15. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs in Fabry Disease.
Xiao K; Lu D; Hoepfner J; Santer L; Gupta S; Pfanne A; Thum S; Lenders M; Brand E; Nordbeck P; Thum T
Sci Rep; 2019 Oct; 9(1):15277. PubMed ID: 31649303
[TBL] [Abstract][Full Text] [Related]
17. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
19. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
